Receptor imaging by PET and SPECT: focus on the opiate receptor.
Receptor imaging by PET and SPECT offers distinctive advantages over the more established flow/metabolism imaging methods, including improved chemical specificity and improved sensitivity in detecting changes in disease. Radioligands are available for PET and SPECT imaging of many neuroreceptors including the opiate receptor, the dopamine receptor and the muscarinic cholinergic receptor. A new focus of interest is the imaging and quantification of presynaptic neurotransmitter reuptake sites. Clinical applications of mu opiate receptor imaging are discussed for epilepsy, Alzheimer's disease and dementia.
Frost
J J
JJ
Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
D000544:Alzheimer Disease / Q000000981:diagnostic imaging; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D003866:Depressive Disorder / Q000000981:diagnostic imaging; D004827:Epilepsy / Q000000981:diagnostic imaging; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism*; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D018377:Neurotransmitter Agents; D011957:Receptors, Opioid